ZAI LAB LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.5 HKD | -3.85% |
|
-4.32% | -27.91% |
ETFs positioned on Zai Lab Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 4 M€ | -11.56% | ||
| 0.28% | 2 M€ | -14.14% | ||
| 0.04% | 2,867 M€ | +11.35% | - | |
| 0.04% | 454 M€ | +9.82% | - | |
| 0.04% | 153 M€ | +9.25% | - | |
| 0.03% | 4 M€ | -4.41% | - | |
| 0.00% | 34 M€ | +3.87% | - |
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
Pharmaceuticals
Calendar
23/05/2024
- J.P. Morgan Global China Summit
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
19.4
USD
Average target price
51.37
USD
Spread / Average Target
+164.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B | |
| -6.32% | 8.35B |
- Stock Market
- Equities
- ZLAB Stock
- 9688 Stock
- Funds and ETFs Zai Lab Limited
